Response of putative indices of copper status to copper supplementation in human subjects

What Was Tested

The paper reports a study of Copper (Supplement), published as a controlled clinical trial.

No sensitive functional index is currently available to assess Cu status in healthy human populations.

Why It Was Studied

This study evaluated the effect of Cu supplementation on putative indices of Cu status in twelve women and twelve men, aged between 22 and 45 years, who participated in a double-blind placebo controlled crossover study.

Erythrocyte and leucocyte superoxide dismutase activity, leucocyte cytochrome c oxidase activity, and erythrocyte glutathione peroxidase activity did not respond to Cu supplementation.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as double-blind, placebo-controlled and crossover.

As a double-blind Copper (Supplement) study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Copper (Supplement), giving a reference point.

In the crossover set-up each of the participants took both Copper (Supplement) and the comparison in turn, acting as their own control.

What Was Measured

This study evaluated the effect of Cu supplementation on putative indices of Cu status in twelve women and twelve men, aged between 22 and 45 years, who participated in a double-blind placebo controlled crossover study.

Topics PubMed links to this paper include Amine Oxidase (Copper-Containing), Ceruloplasmin, Copper, Dietary Supplements, Erythrocytes, Leukocytes and Nutritional Status.

What This Means in Plain Language

The paper is a double-blind, placebo-controlled and crossover study of Copper (Supplement).

The publication is from 2000 (The British journal of nutrition), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.